# Dasatinib for HIV-1 Reservoir Reduction

> **NCT07342491** · PHASE1 · NOT_YET_RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 14 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Dasatinib
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07342491
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2026-11-25
- **Final completion:** 2027-05-12
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07342491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07342491, "Dasatinib for HIV-1 Reservoir Reduction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07342491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*